ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

30 4 2025 17:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

22 4 2025 16:59:59 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

09 4 2025 10:15:25 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

08 4 2025 15:57:55 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

07 4 2025 09:45:16 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

04 4 2025 10:30:54 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

02 4 2025 09:45:05 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

01 4 2025 09:49:27 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

31 3 2025 09:47:05 提供 NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

26 3 2025 11:11:30 提供 NetDania Notify

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 3 2025 17:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in March

24 2 2025 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 2 2025 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

18 2 2025 08:00:01 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

13 2 2025 16:01:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

06 2 2025 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

05 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 1 2025 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

12 1 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 16:30:00 提供 Nasdaq GlobeNewswire